India has the potential to play a key role in overcoming vaccine nationalism because it is the major supplier of medicines to the global south. Médecins Sans Frontières once dubbed the country the “pharmacy of the world
”. India also has, by far, the largest capacity
to produce COVID-19 vaccines. Its role in manufacturing a vaccine could come in two different ways – mass-producing one developed elsewhere (likely) or developing a new vaccine as well as manufacturing it (less likely, though not impossible).
Scaling up existing vaccines
India’s Serum Institute has already started manufacturing the University of Oxford/AstraZeneca vaccine candidate before clinical trials have even been completed. This is to avoid any subsequent delay if the vaccine is approved. It is seen by many, including the WHO’s chief scientist, as the world’s leading prospect.
Serum Institute, based in the western city of Pune, is the largest vaccine manufacturer in the world and has a deal to supply 400 million doses by the end of 2020 (1 billion in total). It has also inked a deal for the manufacturing and commercialisation of American firm Novavax’s COVID-19 candidate.
Another Indian pharma company, Biological E (BE), has agreed to manufacture the vaccine candidate of Johnson & Johnson’s subsidiary, Janssen Pharmaceutica NV. The Hyderabad-based firm has since announced its acquisition of Akorn India in order to boost its manufacturing capacity.
Despite India’s success in mass manufacturing, the transition to innovation and new product development has been more of a struggle. Nevertheless the Serum Institute, Aurobindo Pharma, Bharat Biotech, BE, Indian Immunologicals, Mynvax, Panacea Biotech and Zydus Cadila are all attempting to develop their own vaccines.
Bharat Biotech’s Covaxin has attracted the most attention and controversy. The Indian Council of Medical Research wrote to a number of hospitals seeking their help in fast-tracking the clinical trials of the drug, which was developed in collaboration with the National Institute of Virology. The aim had been to launch it by August 15 (Indian Independence Day). Despite the feasibility of that timeline being widely questioned, trials of Covaxin did begin in Delhi on July 15.
Who gets the vaccines?
Uncertainty reigns over who will get these vaccines manufactured in India – and there have been very mixed messages. Regarding the much-hyped Oxford/AstraZeneca vaccine, Adar Poonawalla, the Serum Institute’s CEO, said, “a majority of the vaccine, at least initially, would have to go to our countrymen before it goes abroad”.
He added that the Indian government would decide how much other countries get, and when. In a later interview the CEO went further, adding: “Out of whatever I produce, 50% to India and 50% to the rest of the world”. He also said the Indian government had not objected to this idea.
Vaccine diplomacy may come into play, as indicated by India’s foreign minister, Harsh Shringla, on a visit to Dhaka. He promised that India would supply vaccines to Bangladesh on “priority basis”, stating that India’s “closest neighbours, friends, partners and other countries” will receive privileged access.
Meanwhile, a recent agreement provided a firmer guarantee of Serum-Institute-produced vaccines being supplied outside of the country – at least in 2021. On August 7, Gavi (the global vaccine alliance) announced a collaboration with the Serum Institute and the Bill & Melinda Gates Foundation. The deal provides US$150m of financial support for the Serum Institute to manufacture and supply 100 million doses of vaccines to the COVID-19 Vaccine Global Access Facility (COVAX) for distribution in low and middle-income countries in 2021.
The deal will support the company’s manufacture of both the AstraZeneca and Novavax candidates and guarantees a price of US$3 per dose. AstraZeneca’s candidate will be available to 57 Gavi-eligible countries, while the Novavax treatment will be available to 92.
With almost 18% of the world’s population, India has strong demand for COVID-19 vaccines. Export bans on some personal protective equipment and key medicines in March set a precedent for prioritising supply to India first. But the bans were short lived and exports continued.
Thanks to its vast manufacturing capacity, India will undoubtedly export vaccines, continuing its role as the “pharmacy of the developing world”. Vinod Paul, chair of India’s National COVID-19 Task Force, has spoken openly of his desire to see India play a global role, saying: “The vaccine is not just for India and Indians but for the world and humanity.” The question is when. Many in low and middle-income countries will undoubtedly be hoping it will be sooner rather than later.
Rory Horner, Senior Lecturer, Global Development Institute,
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.